European CHMP recommends licence extension of atezolizumab (Tecentriq)

The CHMP has recommended approval of atezolizumb, in combination with bevacizumab, for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.

European Medicines Agency